A June (2021) article by Steve Kirsch at OneDayMD.com (who’s that?) is critical of NIH and WHO COVID-19 treatment guidelines. Steve argues, and I must say fairly persuasively, that early treatment should include ivermectin and fluvoxamine. Parts of the world don’t have time to wait for results of large randomized double-blind controlled trials of these drugs. RTWT and decide for yourself if Steve’s right. Warning: It’s a long article but worth it if you’re a healthcare professional.
Who is Steve Kirsch? In his article, Steve mentions that he’s an MIT-trained engineer. From OneDayMD.com:
Steve Kirsch is a high-tech serial entrepreneur based in Silicon Valley. He has been a medical philanthropist for more than 20 years. When the pandemic started, he left his day job at M10 and started the COVID-19 Early Treatment Fund (CETF), which funds researchers from all over the world running outpatient clinical trials on repurposed drugs. CETF funded David Boulware’s trials on hydroxychloroquine and the Phase 2 and Phase 3 fluvoxamine trials, among many other research projects. He was recently featured on 60 Minutes, which highlighted his work with fluvoxamine. He has no conflicts of interest; his objective is to help save lives. In 2003, Hillary Clinton presented him with a National Caring Award. He wrote this article to share some of what he has learned over the past year about the failure of evidence-based medicine during a pandemic in the hopes that people will realize their mistakes and change their views.
Steve Parker, M.D.